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That genome-wide association studies (GWAS) are an effective strategy to identify underlying genetic susceptibility for complex diseases is undisputable. At the time of this writing, 3172 publications have reported 52,491 unique single-nucleotide polymorphism (SNP)-trait associations according to the GWAS Catalog, a database that tracks large, genome-wide studies. With more than 200 genome-wide, replicated associations, multiple sclerosis (MS) is one of the most resounding success stories of the GWAS paradigm. Part of the success of this approach results from the large number of samples studied, which in turn highlights the collaborative, multi-center nature of these studies. However, as a consequence of this, increasingly smaller effects are being detected. Then, the question becomes "when do we stop searching?" Some researchers may argue that GWAS have reached a point of diminishing returns and that it is no longer cost-effective to keep assembling and genotyping larger cohorts (even when the price of genotyping continues to drop on a yearly basis). This point of view is represented here by Koen Vandenbroeck. While this is a plausible argument, it assumes that the only benefit of GWAS is the identification of susceptibility loci. Phil de Jager presents the opposite view and argues that associations with more detailed (endo)phenotypes can be detected by GWAS if these are measured with precision in large, homogeneous cohorts. These phenotypes include severity of disease, response to disease modifying therapies, and quantitative traits of importance to MS such as vitamin D levels, anti-Epstein-barr nuclear antigen (EBNA) titers, or neurofilament concentrations. In addition, GWAS could still be useful in unraveling the genetic architecture of MS in nonEuropean populations where MS is prevalent, such us African Americans, Middle Eastern, and Latino.
As Koen Vandenbroeck points out, GWAS only have the potential to identify association with DNA variants that are common in the population (typically present in at least in 5% of individuals). This strategy would then miss any association with rare variants. However, a recent study in type 2 diabetes with more than 100,000 subjects indicates that variants associated with this disease after sequencing were overwhelmingly common and most fell within regions previously identified by GWAS. 1 Another argument made against more GWAS in MS is that there are already a large number of loci in which to conduct functional studies. Arguably, these studies would provide the ultimate evidence that susceptibility to MS is genetically determined and uncover which cellular pathways are most likely responsible for MS risk. The identification of cellspecific expression quantitative trait loci (eQTL), gene regulatory pathways, and epigenetic mechanisms regulated by the more than 200 MS-associated variants 2 awaits and will undoubtedly brings us closer to understanding genetic risk to MS. At the same time, with some additional data gathering, many of the large cohorts already assembled to study susceptibility could also be used to study the additional phenotypes described above, thus absorbing most of the cost of identifying, consenting and recruiting subjects. Thus, it is entirely possible that both GWAS and functional studies will continue to guide genetic discoveries in MS for the foreseeable future.
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